Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lcr Regenerans intravaginal prevention study in recurrent vulvovaginal candidiasis
2013-002480-26Phase 3Completed
- Sponsor
- Biose Industrie
- Start
- Jul 2014
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lactobacillus rhamnosus in recurrent vulvovaginal candidiasis (RVVC) (2 arms), sponsored by Biose Industrie. Primary endpoint: Primary efficacy endpoint. Started Jul 2014; status: completed.
02
Drugs
lactobacillus rhamnosus
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on 2013-002480-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002480-26.